

EuroValves 2015, Nice



Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis?

Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC

Canada Research Chair in Valvular Heart Diseases



INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC






**Université
LAVAL**

Disclosure Statement

- **Edwards Life Science: Research grant for Echo Core Lab, transcatheter aortic and mitral valve replacement**
- **V Wave Ltd.**


Etiology of High Doppler Gradients in Prosthetic Heart Valves

- **Prosthesis-patient mismatch i.e. too small a prosthesis in too large a patient**
- **Prosthesis dysfunction due to an acute (e.g. thrombus), subacute (e.g. endocarditis) or chronic process (e.g. pannus, calcific degeneration in bioprosthesis)**
- **Central localized high velocity jet in bileaflet prosthesis**
- **Occult mitral prosthesis regurgitation**







Transvalvular Flow Pattern in Bioprosthesis vs. Mechanical Prosthesis



Courtesy B. Little



Peak Prosthetic Aortic Jet Velocity > 3 m/s



$$\text{Doppler Velocity Index} = \frac{\text{Velocity}_{\text{LVO}}}{\text{Velocity}_{\text{jet}}}$$

DVI
≥ 0.30

DVI
0.25 – 0.29

DVI
< 0.25

Jet Contour

AT (ms)

>100

<100

>100

<100

Consider PrAV stenosis with

- Sub-valve narrowing
- Underestimated gradient
- Improper LVOT velocity*

Normal PrAV

Suggests PrAV Stenosis ϕ

Consider Improper LVOT velocity**

EOA Index


High Flow

PPM


Zoghbi et al.
J Am Soc Echocardiogr,
22:975-1014, 2009.

Gradient, EOA, and DVI for Evaluation of Aortic Prosthetic Valve Function


Peak Gradient (mmHg)



EOA (cm²)




DVI



Zekry et al.
J Am Coll Cardiol Img
2011;4:1161-70

Ratio of Acceleration Time to Ejection Time for Aortic Prosthetic Valve Function



Criteria for PV stenosis:


AT > 100 ms

AT/LVET > 0.37


Zekry et al.

J Am Coll Cardiol Img

2011;4:1161-70




Dysfunction of Bileaflet Aortic Valves: Doppler-Echo vs. Cinefluoroscopy




Evaluation of Leaflet Morphology & Mobility: A Cornerstone of Identification of Prosthetic Valve Dysfunction

Normal





Abnormal



Bioprosthesis


Mechanical



Evaluation of Leaflet Mobility: Usefulness of Cinefluoroscopy in Mechanical Valves


Normal

Abnormal



HEMO04
Ex: 20070001265101
Se: 1/6
Im: 5/45 (Fr: 1/45)

Hop Laval
ANON0000
1944 Sep 23 F 381617
Acc: 20070001265101
2007 Feb 07
Acq Trm: 12:26:17.000000



Id:DCM / Lin:DCM / Id:ID
W:256 L:128

High Gradient after AVR

**Prosthesis-Patient
Mismatch**

Severity? <0.65 : severe

Yes

Step 1

**Predicted Indexed
EOA $<0.85\text{cm}^2/\text{m}^2$?**

**Normal
reference
EOA / BSA**

Step 2

Abnormal leaflet morphol/ mobility
DVI <0.30 (<0.25)
EOA $<$ reference EOA ($\Delta >0.35\text{cm}^2$)
Gradient increased during FU
EOA & DVI decreased during FU
AT/ET >0.37

**Cine-
fluoro**

Yes

**Consider
Prosthesis
Stenosis**

No



Consider:

High Flow state / aortic regurgitation
Subvalvular obstruction
Technical error
Localized high gradient (bileaflet valve)

Case Study : High Doppler Gradient in Aortic Valve Prosthesis

72 y.o. patient with Carbomedic # 19 aortic prosthesis (3 years) :

- **NYHA class II-III**
- **Moderate diastolic dysfunction**
- **Pulmonary arterial hypertension (systolic PA pressure: 50 mmHg)**



Peak Gradient = 69 mm Hg
Mean Gradient = 40 mmHg

Question no. 1

What is the cause of the high gradient in this patient ?

- a. Valve prosthesis dysfunction (thrombus / pannus)?**
- b. Valve prosthesis-patient mismatch?**
- c. Central localized high velocity jet?**



High Gradient after AVR



Step 1


Predicted Indexed
EOA < 0.85 cm²/m²?

BSA = 1.95 m²

Reference
EOA = 1.0 cm²

= 0.51 cm²/m²

Severe Prosthesis-Patient Mismatch!



Carbomedics
19 mm



Table 2 Normal reference values of effective orifice areas for the prosthetic valves


| Prosthetic valve size (mm) | 19 | 21 | 23 | 25 | 27 | 29 | Reference |
|---------------------------------------|---------|---------|----------|----------|---------|---------|-----------|
| Stented bioprosthetic valves | | | | | | | |
| Mosaic | 1.1±0.2 | 1.2±0.2 | 1.4±0.3 | 1.7±0.4 | 1.8±0.4 | 2.0±0.4 | w8 |
| Hancock II | — | 1.2±0.2 | 1.3±0.2 | 1.5±0.2 | 1.6±0.2 | 1.6±0.2 | w8 |
| Carpentier-Edwards Perimount | 1.1±0.3 | 1.3±0.4 | 1.50±0.4 | 1.80±0.4 | 2.1±0.4 | 2.2±0.4 | w8 |
| Carpentier-Edwards Magna | 1.3±0.3 | 1.5±0.3 | 1.8±0.4 | 2.1±0.5 | — | — | w9, w10 |
| Biocor (Epic) | 1.0±0.3 | 1.7±0.5 | 1.4±0.5 | 1.9±0.7 | — | — | w11, w12 |
| Mitroflow | 1.1±0.2 | 1.2±0.3 | 1.4±0.3 | 1.6±0.3 | 1.8±0.3 | — | w13 |
| Stentless bioprosthetic valves | | | | | | | |
| Medtronic Freestyle | 1.2±0.2 | 1.4±0.2 | 1.5±0.3 | 2.0±0.4 | 2.3±0.5 | — | w8 |
| St Jude Medical Toronto SPV | — | 1.3±0.3 | 1.5±0.5 | 1.7±0.8 | 2.1±0.7 | 2.7±1.0 | w8 |
| Mechanical valves | | | | | | | |
| Medtronic-Hall | 1.2±0.2 | 1.3±0.2 | — | — | — | — | w8 |
| St Jude Medical Standard | 1.0±0.2 | 1.4±0.2 | 1.5±0.5 | 2.1±0.4 | 2.7±0.6 | 3.2±0.3 | w8 |
| St Jude Medical Regent | 1.6±0.4 | 2.0±0.7 | 2.2±0.9 | 2.5±0.9 | 3.6±1.3 | 4.4±0.6 | w14 |
| MCRI On-X | 1.5±0.2 | 1.7±0.4 | 2.0±0.6 | 2.4±0.8 | 3.2±0.6 | 3.2±0.6 | w15 |
| Carbomedics Standard and Top Hat | 1.0±0.4 | 1.5±0.3 | 1.7±0.3 | 2.0±0.4 | 2.5±0.4 | 2.6±0.4 | w8 |
| ATS Medical* | 1.1±0.3 | 1.6±0.4 | 1.8±0.5 | 1.9±0.3 | 2.3±0.8 | — | w16 |

Question no. 2

Is there any intrinsic dysfunction in addition to prosthesis-patient mismatch?

Case Study : High Doppler Gradient in Aortic Valve Prosthesis

68 y.o. patient
3 Years post AVR
Carbomedic # 19



Reference EOA

1.0 ± 0.4

Measured EOA = 1.06 cm^2

BSA = 1.95 m^2

Predicted


Indexed EOA:

$0.51 \text{ cm}^2/\text{m}^2$

Measured

Indexed EOA:

$0.55 \text{ cm}^2/\text{m}^2$



High Gradient after AVR

**Prosthesis-Patient
Mismatch**
Severity? <0.65 : severe

Yes

Step 1
Predicted Indexed
EOA $<0.85 \text{ cm}^2/\text{m}^2$?

Normal
reference
EOA / BSA

Step 2

Abnormal leaflet morphol/ mobility
DVI <0.30 (<0.25)
EOA $<$ reference EOA ($\Delta >0.35 \text{ cm}^2$)
Gradient increased during FU
EOA & DVI decreased during FU
AT/ET >0.37

Cine-
fluoro

Yes

**Consider
Prosthesis
Dysfunction**

No


Consider:

High Flow state / subvalvular obstruction
Technical error
Localized high gradient (bileaflet valve)

Intraoperative echo after prosthesis implantation

St. Jude Regent # 21
Suprannular
(reference EOA: 2.0 cm²)

Stroke volume: 64 mL
Heart rate: 98 bpm
Peak gradient: 21 mmHg
Mean gradient: 14 mmHg




Dumesnil & Pibarot, in Book:
Transesophageal Echocardiography
Multimedia Manual: 361, 2005

Case Study #2

- **62 y.o. woman**
- **BSA: 1.3 m²**
- **History of Barlow disease**
- **MVR 1 year ago with a MCRI OnX #25 mechanical valve**
- **INR within target since MVR**
- **Asymptomatic**
- **Recruited for a research project**

Echocardiogram



Peak Gradient = 11 mmHg

Mean Gradient = 6 mmHg

DVI : 2.4

Measured EOA = 1.1 cm²

Doppler-Echo Evaluation of Mitral Prosthesis - Specifics

- **Doppler Velocity Index: $VTI_{mvp} / VTI_{lvot} (>2.2)$**
- **EOA calculated using continuity equation as follows : $EOA = SV_{lvot} / VTI_{mvp}$ (Not valid if significant aortic or mitral regurgitation)**
- **Pressure half-time not valid to calculate EOA (grossly overestimates) but may be useful for serial comparisons or if delayed (>130 msec)**

Question no. 1

Is valve prosthesis-patient mismatch a consideration in this case?

High Gradient after MVR

Prosthesis-Patient Mismatch

Severity? <0.9 : severe

Yes

Step 1

Predicted Indexed EOA $<1.2 \text{ cm}^2/\text{m}^2$?

Normal reference EOA / BSA

Step 2

**Abnormal leaflet morphol/ mobility
DVI >2.2
EOA $<$ reference EOA ($\Delta >0.4 \text{ cm}^2$)
Gradient increased during FU
EOA decreased during FU**

Cine-fluoro

Yes

Consider Prosthesis Stenosis a/o Regurgitation

No

Consider:

**High flow state
Technical error
Localized high gradient (bileaflet valve)**

Normal Reference Values of EOAs for Mitral Prostheses

Table 2. Normal Reference Values of EOAs for the Mitral Prostheses

| | Prosthetic Valve Size, mm | | | | | Reference |
|-------------------------------|---------------------------|---------|---------|---------|---------|-----------|
| | 25 mm | 27 mm | 29 mm | 31 mm | 33 mm | |
| Stented bioprosthesis | | | | | | |
| Medtronic Mosaic | 1.5±0.4 | 1.7±0.5 | 1.9±0.5 | 1.9±0.5 | ... | 15, 28 |
| Hancock II | 1.5±0.4 | 1.8±0.5 | 1.9±0.5 | 2.6±0.5 | 2.6±0.7 | 29 |
| Carpentier-Edwards Perimount* | 1.6±0.4 | 1.8±0.4 | 2.1±0.5 | ... | ... | 28 |
| Mechanical prostheses | | | | | | |
| St Jude Medical Standard | 1.5±0.3 | 1.7±0.4 | 1.8±0.4 | 2.0±0.5 | 2.0±0.5 | 28 |
| MCRI On-X† | 2.2±0.9 | 2.2±0.9 | 2.2±0.9 | 2.2±0.9 | 2.2±0.9 | 28 |

Answer: Calculate predicted indexed EOA to exclude PPM

Predicted EOA for
OnX #25



2.2 cm²



BSA = 1.30 m²

Predicted Indexed EOA = 1.7 cm²/m²



0.9




1.2

Indexed EOA
(cm²/m²)

Question no. 2

Should we suspect a prosthesis dysfunction?

Answer : Compare the measured EOA to the normal reference EOA



Measured EOA= 1.1 cm²

Reference value= 2.2 cm²!!

Question no. 3


Differential diagnosis:

- a- Prosthesis dysfunction in this case?**
- b- Central high velocity jet in bileaflet mechanical prosthesis?**


Answer

Evaluate **leaflet mobility** using either
TEE / fluoroscopy / CT

Leaflet Mobility by TTE



Cinefluoroscopy



Transthoracic Echocardiogram


TIS: 1.0
S3
06 FEB 07
14:15:34
2/0/N/M/A
HOPITAL LAVAL
RECHERCHE
RECHERCHE

MVS-06B


GAIN 47
COMP 50
86BPM

14CM
16HZ

T
P 1.6 3.2 R





Transesophageal Echocardiogram





Mitral prosthesis

Aortic prosthesis

Parasternal



Apical



High Gradient after MVR

**Prosthesis-Patient
Mismatch**

Severity? <0.9 : severe

Yes

Step 1

Predicted Indexed
EOA $<1.2 \text{ cm}^2/\text{m}^2$?

Normal
reference
EOA / BSA

Step 2

Abnormal leaflet morphol/ mobility
DVI >2.2
EOA $<$ reference EOA ($\Delta >0.4 \text{ cm}^2$)
Gradient increased during FU
EOA decreased during FU

Cine-
fluoro


Yes

**Prosthesis
Stenosis &
Regurgitation**



No

Consider:

High flow state
Technical error
Localized high gradient (bileaflet valve)



3D Echo for Evaluation of Prosthetic Valve Function



Case #1

- 3 yr. post AVR
- Carbomedics 19
- NYHA III
- Echo
 - Gradients: 69/40
 - EOA: 1.1 cm²
- **Severe PPM**

Case #2

- 1 yr. Post MVR
- OnX 25
- Asymptomatic
- Echo
 - Gradients: 11/6
 - EOA: 1.1 cm²
- **Severe dysfunction:
Thrombus**

Key Points

- **High gradient does not always mean prosthesis dysfunction**
- **Low gradient does not always mean normal prosthesis function**
- **Multi-parametric approach is key to appropriately differentiate normal function vs. PPM vs. dysfunction**

Key Points

PPM

- High Gradient
- Small indexed EOA
- EOA ~ normal
- Intermediate DVI
- Intermediate AT/LVET
- Normal leaflet morphology / mobility

Dysfunction

- High Gradient
- Small indexed EOA
- EOA \ll normal
- Small DVI
- Low AT/LVET
- Abnormal leaflet morphology / mobility





INSTITUT UNIVERSITAIRE
DE CARDIOLOGIE
ET DE PNEUMOLOGIE
DE QUÉBEC

← Entrée du
personnel
seulement



Recommendations for Evaluation of Prosthetic Valves With Echocardiography and Doppler Ultrasound

A Report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, Developed in Conjunction With the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, Endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography

William A. Zoghbi, MD, FASE, Chair, John B. Chambers, MD,* Jean G. Dumesnil, MD,[†] Elyse Foster, MD,[‡] John S. Gottdiener, MD, FASE, Paul A. Grayburn, MD, Bijoy K. Khandheria, MBBS, FASE, Robert A. Levine, MD, Gerald Ross Marx, MD, FASE, Fletcher A. Miller, Jr., MD, FASE, Satoshi Nakatani, MD, PhD,[§] Miguel A. Quiñones, MD, Harry Rakowski, MD, FASE, L. Leonardo Rodriguez, MD, Madhav Swaminathan, MD, FASE, Alan D. Waggoner, MHS, RDCS, Neil J. Weissman, MD, FASE,^{||} and Miguel Zabalgoitia, MD, *Houston and Dallas, Texas; London, United Kingdom; Quebec City, Quebec, Canada; San Francisco, California; Baltimore, Maryland; Scottsdale, Arizona; Boston, Massachusetts; Rochester, Minnesota; Suita, Japan; Toronto, Ontario, Canada; Cleveland, Ohio; Durham, North Carolina; St Louis, Missouri; Washington, DC; Springfield, Illinois*

Useful References

Zoghbi et al. *J Am Soc Echocardiogr*, 22:975-1014, 2009

Education in Heart

VALVULAR HEART DISEASE

Doppler echocardiographic evaluation of prosthetic valve function

Philippe Pibarot,¹ Jean G Dumesnil²

**Pibarot & Dumesnil *Heart* 2012;
98:69-78, 2012**

EXPERT CONSENSUS STATEMENT

EAE/ASE Recommendations for the Use of Echocardiography in New Transcatheter Interventions for Valvular Heart Disease

Jose L. Zamorano^{1*†}, Luigi P. Badano², Charles Bruce³, Kwan-Leung Chan⁴, Alexandra Gonçalves⁵, Rebecca T. Hahn⁶, Martin G. Keane⁷, Giovanni La Canna⁸, Mark J. Monaghan⁹, Petros Nihoyannopoulos¹⁰, Frank E. Silvestry⁷, Jean-Louis Vanoverschelde¹¹, and Linda D. Gillam^{12‡}, *Rochester, Minnesota; Ottawa, Ontario, Canada; Porto, Portugal; New York, New York; Philadelphia, Pennsylvania; London, United Kingdom; Brussels, Belgium; Morristown, New Jersey*

Zamorano JL; *J Am Soc Echocardiogr* 2011;24:937-65